6 x Pharmaqo SR9009 (STENABOLIC) 15mg x 60

Description

6 x Pharmaqo SR9009 (STENABOLIC) 15mg x 60

6 x Pharmaqo SR9009 (STENABOLIC) 15mg x 60 is a bulk listing for SR9009, commonly known as Stenabolic. The listing contains 6 packs of 60 units, providing 360 units in total, with a stated strength of 15mg per unit.

SR9009 is an experimental REV-ERB agonist, not a conventional SARM. It has been investigated primarily in laboratory and animal research involving circadian rhythm, metabolism, mitochondrial activity and energy regulation. It is not an established UK-authorised medicine, and there is insufficient clinical evidence to establish a safe and effective human treatment regimen.

The specific Pharmaqo product should not be assumed to have pharmaceutical-grade purity, verified potency or UK marketing authorisation.

Classification

Product name: Pharmaqo SR9009 (STENABOLIC)
Active compound: SR9009 / Stenabolic
Listed strength: 15mg per unit
Pack size: 60 units
Bulk quantity: 6 packs
Total units: 360
Classification: Experimental REV-ERB agonist

SR9009 should not be classified as a SARM. It was developed as a research compound designed to interact with the REV-ERB nuclear receptors.

What is 6 x Pharmaqo SR9009 (STENABOLIC) 15mg x 60?

6 x Pharmaqo SR9009 (STENABOLIC) 15mg x 60 is a bulk presentation of a product labelled as SR9009 or Stenabolic.

SR9009 was developed as a synthetic agonist of REV-ERBα and REV-ERBβ, nuclear receptors involved in regulation of circadian rhythms and metabolic processes.

Research has explored whether manipulating REV-ERB signalling could influence energy metabolism, mitochondrial function and physical activity. Much of the evidence, however, comes from laboratory and animal models rather than established human clinical trials.

The stated 15mg is the labelled product strength and should not be interpreted as a validated therapeutic dose.

Dosage

There is no established UK-authorised human dosing regimen for Pharmaqo SR9009 (STENABOLIC) 15mg x 60.

The stated 15mg strength should therefore not be presented as a recommended daily dose or as part of a bodybuilding or fat-loss protocol.

Because SR9009 remains an experimental compound, its pharmacokinetics, long-term safety, appropriate human dose and clinically relevant therapeutic window have not been sufficiently established.

How Does Pharmaqo SR9009 (STENABOLIC) 15mg x 60 Work?

SR9009 works experimentally by activating REV-ERB nuclear receptors.

REV-ERBα and REV-ERBβ are transcriptional regulators involved in the body’s molecular clock and metabolic regulation. Experimental activation of these receptors can alter the expression of genes involved in processes such as lipid metabolism, glucose metabolism and mitochondrial function.

Animal research has reported changes in metabolic activity and physical performance following REV-ERB activation. These findings do not establish that the same effects, or an equivalent safety profile, occur in humans.

Potential Benefits

Research involving SR9009 has investigated several potential biological effects, including:

• Regulation of circadian-related pathways
• Alteration of metabolic gene expression
• Effects on lipid metabolism
• Effects on glucose metabolism
• Changes in mitochondrial activity
• Experimental effects on physical activity and endurance

These should be regarded as research findings rather than proven clinical benefits.

There is currently insufficient evidence to describe SR9009 as an established treatment for obesity, diabetes, fatigue, metabolic disease or impaired physical performance.

When Should You Not Take Pharmaqo SR9009 (STENABOLIC) 15mg x 60?

Because SR9009 is not an established UK-authorised medicine, there is no standard UK prescribing framework defining approved contraindications.

Particular caution is warranted for individuals with:

• Liver disease
• Kidney disease
• Cardiovascular conditions
• Metabolic disorders
• Hormonal disorders
• Pregnancy or breastfeeding
• Known hypersensitivity to the product’s ingredients
• Existing medicines that could potentially interact with experimental compounds

Anyone considering an investigational compound should discuss the situation with an appropriately qualified healthcare professional.

Mechanism

SR9009 is a synthetic REV-ERB agonist.

REV-ERB receptors act as transcriptional regulators and form part of the molecular mechanisms controlling circadian rhythm. They also influence genes involved in metabolism.

By activating REV-ERB signalling, SR9009 can alter transcription of downstream genes involved in metabolic and cellular processes.

Preclinical research has reported effects involving mitochondrial function, lipid metabolism and energy expenditure. However, these experimental mechanisms should not be interpreted as evidence of a clinically proven fat-loss or performance-enhancing effect in humans.

Uses

SR9009 is primarily of research interest rather than being an established therapeutic medicine.

Experimental studies have investigated REV-ERB signalling in areas including:

• Circadian biology
• Metabolism
• Mitochondrial function
• Lipid metabolism
• Energy regulation
• Muscle and exercise research

The compound should not be marketed as an approved treatment for weight loss, obesity, diabetes, muscle development or athletic performance.

Warnings and Precautions

The principal concern with SR9009 is the limited amount of reliable human safety information.

A compound can produce interesting results in laboratory or animal research without being safe or effective in humans. The absence of an established therapeutic dose also makes self-directed use particularly difficult to assess.

Important considerations include:

• Long-term human safety is not established.
• Appropriate human dosing has not been validated.
• Product purity may vary between suppliers.
• The stated strength should not automatically be assumed to have been independently verified.
• Potential drug interactions may not be adequately characterised.
• Effects on metabolic and circadian pathways could have consequences beyond the intended research target.

Side Effects

A complete human side-effect profile for SR9009 has not been established.

Because clinical safety data are limited, it would be inappropriate to provide a definitive list of expected adverse reactions or imply that the compound is safe at the stated 15mg strength.

Potential concerns with an experimental metabolic compound may include unexpected effects on:

• Liver function
• Metabolic regulation
• Cardiovascular function
• Sleep and circadian rhythms
• Hormonal pathways
• Gastrointestinal function

Unexplained or severe symptoms following exposure to an experimental compound warrant medical assessment.

Storage

Store 6 x Pharmaqo SR9009 (STENABOLIC) 15mg x 60 according to the manufacturer’s original storage instructions.

As a general precaution:

• Keep the product in its original packaging.
• Protect it from excessive heat and moisture.
• Keep away from direct sunlight where applicable.
• Store securely away from children.
• Do not use beyond the stated expiry date.
• Do not use units where the packaging appears damaged or compromised.

Where to Buy 6 x Pharmaqo SR9009 (STENABOLIC) 15mg x 60?

To get 6 x Pharmaqo SR9009 (STENABOLIC) 15mg x 60 online, go to Steroid Sanctuary today to get the best deal on this medicine.

Frequently Asked Questions

1. What is 6 x Pharmaqo SR9009 (STENABOLIC) 15mg x 60?

It is a bulk listing containing 6 packs of 60 units, giving 360 units in total, with a stated strength of 15mg per unit.

2. Is SR9009 a SARM?

No. SR9009 is generally classified as an experimental REV-ERB agonist, rather than a selective androgen receptor modulator.

3. What is SR9009 also called?

SR9009 is commonly referred to as Stenabolic. It was developed as an experimental compound targeting REV-ERBα and REV-ERBβ receptors.

4. Is SR9009 approved for human use?

SR9009 is not an established UK-authorised medicine, and there is insufficient clinical evidence to establish a validated human therapeutic dose or long-term safety profile.

5. How many units are included in 6 x Pharmaqo SR9009 (STENABOLIC) 15mg x 60?

The listing contains 6 × 60 units, giving 360 units in total, with a stated 15mg strength per unit.